Key Drivers
- Strong Liquidity
- Weak Profitability
- Mixed Valuation
AIAI Summary
ANGO has shifted from a speculative turnaround to a credible med-tech growth story, but with profitability still fragile, the key takeaway is that investors should watch whether Auryon, thrombectomy, and especially NanoKnife can sustain momentum fast enough to outrun tariff/manufacturing margin pressure and deliver a real earnings inflection.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Weak Profitability
- •Mixed Valuation
ANGO has a strong cash-rich, debt-free balance sheet and solid gross margins, but persistent losses and weak returns keep the investment case dependent on future profitability rather than current earnings.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Range breakout
- •Volatility risk
ANGO has shifted from a choppy base to a short-term uptrend over the last month, holding higher lows above its moving average, but it is now stretched near $14.79 resistance and vulnerable to a pullback if $13.66–$13.44 support breaks.
Sharp mid-month swing and rapid rebound signal elevated short-term volatility risk
Sentiment & News
Key News Insights:
- •Revenue Beat
- •Margin Expansion
- •FY27 Guidance
AngioDynamics beat Q4 and FY26 expectations with stronger revenue, margin expansion, and upbeat FY27 guidance, signaling improving momentum toward sustained profitability.
The results and guidance suggest improving operating leverage and investor sentiment, which could support the stock if execution continues
Similar Companies in Healthcare
Other companies in the same sector with AI ratings